Depends what RHT acquires with the money Nutsy , they may be onto to something ?
The Company’s R&D strategy includes diversification of inhouse R&D as outlined below, potential licencing of out-of-house technologies (such as that detailed in the ASX announcement dated 3 January 2019 “Execution of Licence Agreement for use of Patents”, and potential acquisitions of new medical diagnostic and treatment technologies. The current R&D initiatives include, but are not limited to, the following (please note that due to the competitive and confidential nature of R&D, particular details of projects, and projects themselves, may be withheld in order to protect Company intellectual property):
Ann: R&D Activities Update and Appendix 3B, page-26
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
